The Russian developers of the 'Grippol Plus' flu vaccine have agreed on a partnership with Iranian counterparts who will localize production of the vaccine in Iran.
Russian pharmaceutical firm Petrovax and two Iranian manufacturers have signed an agreement to localize the production of the 'Grippol Plus' influenza vaccine in Iran.
The 'Grippol Plus' vaccine is given to children and pregnant women to prevent them falling ill with flu, and is sold throughout the Commonwealth of Independent States and in some EU countries, for example Slovakia.
After extensive testing in the Islamic Republic, doctors there decided that the vaccine would be a welcome addition to their medical arsenal, and Iranian manufacturers of pharmaceuticals asked Petrovax for the right to produce the vaccine, Petrovax President Yelena Arhangelskaya told Sputnik.
"We made the first delivery of 'Grippol Plus' to Iran in 2015 and got positive reviews from Iran's Ministry of Health and the relevant medical specialists. After that we got an offer from Iranian company Sobhan Recombinant Protein for the transfer of technology to produce 'Grippol Plus.'"